Clinical Research For Gene Polymorphism Of GSTT1 And Susceptibility Of Ovarian Cancer

Objectice:The progression of ovarian cancer comprises multiple steps and multifactors.The mortality of ovarian cancer is the highest in the female genital malignancies.Its 5-year survival is estimated at 25%.Although the improvement of operative skills and application of chemotherapeutics such as platinum and paclitaxel, the 5-year survival doesn't have any improvement.The major cause of high mortality results from advanced ovarian cancer when it is diagnosed. Therefore,searching the high suseptible genetic markers is significantly important to prevention,diagnosis,the guidance of clicical treatment and improvement of prognosis of ovarian cancer.Enviromental and hereditary factors are mainly responsible for ovarian tumors. The remove of environmental carcinogens in vivo requires two-step pretreating prosesses,namely effect of stage I and stage II metabolic enzymes.Glutathione S-transferase theta-1(GSTT1) which belongs to stage II metabolic enzymeis is high hereditary suseptible.We detected the GSTT1 genetic polymorphism in peripheral blood from 89 patients with ovarian cancer,and analyzed the relationship between deletion of GSTT1 gene and ages of onset,pathologic typing,clinical staging of patients with ovarian cancer.Throughing approaching correlation of GSTT1 genetic polymorphism with suseptibility to ovarian cancer,we respect to provide cilinical evidence for early diagnosis.Method:From 2005 to 2007,eighty-nine patients with ovarian cancer and forty-nine the control who undewent operation and specimens were finally diagnosed by pathologists as ovarian malignancies at the China-Japan Union Hospital of Jilin University were chose randomly.Retrospective analysis of between ages of onset, clinical manifestations,pathologic typing,diagnosis and treatment GSTT1 genetic polymorphism of 89 ovarian cancer patients and 49 the controls.Result:1.The median age is 52±14.8 years old of 89 patients with ovarian cancer(range from 18 to 75).The median age is 50±10.6 years old of 49 the contrls(range from 25 to 66).Seventy patients who manifested as abdomenal tumeur account 78.7%;Ten patients who were detected unexpectedly account 11.2%;Five who manifested as vaginal irregular bleeding and sencondary modest,severe aneamia acccount 5.6%;Four who had dysuria and difficult defecation account 4.5%.According to FIGO staging,of these patients, stage I patients are 10 cases,accout 11.2%;stage II are 24 cases,accout 27.0%;stageⅢare 35 cases,accout 39.3%;Ⅳare 20 cases,accout 22.5%.According to classification of histology,epithelial ovarian tumors are 70 cases,account 78.7%; serous cystadenocarcinoma are 46 cases, mucinous cystadenocarcinoma are 12,endometroid carcinoma are 10,other kinds of carcinoma are 2 cases.non-epithelial ovarian tumors are 19 cases,account 21.3%;dysgerminoma are 3 cases,immature teratoma are 3,endodermal sinus tumot 3,granulosa cell tumor are 6,metastatic ovarian tumor are 2.2. The GSTT1 null genotype was observed in 12.2% of the controls that had never suffered from neoplastic disease (n = 49) and in 34.8% of the patients affected with ovarian cancer (n = 89,χ2=8.22,OR 2.58, 95% CI 1.39～5.83). The rate of GSTT1 null genotype in early-stage patients and advanced stage patients are 41.2%(14/34), 30.9%(17/55)respectively.There are no statistic difference between early-stage and advanced stage patients.The rate of GSTT1 null genotype in patients with epithelial ovarian tumors and non-epithelial ovarian tumors are 41.4%(29/70),10.5%(2/19) respectively.There is significant difference between epithelial ovarian cancer and the contrl for The GSTT1 null genotype(χ2=11.8,p<0.05), The GSTT1 null genotype chief increase risk of epithelium ovarian tumor(OR 0.86,95% CI 0.22～3.29). Similarly,no significant differences were obtained if GSTT1 null genotypes were analyzed in ubgroups of control subjects and non-epithelial ovarian cancer patients.Conclusion:1 The median age of onset of ovarian cancer is 52 years old and the age of majority of patients is between 50 an 70.2 Clinical findings of ovarian cancer patients contain abdomenal pain ,abdomenal distention and ascites.3 Among all histopathologic categories of ovarian cancer, the incidence of epithelial ovarian tumor is the highest. 4 There are positive correlation between Genetic polymorphism of GSTT1 and susceptibility to patients with ovarian cancer.5 Deletion of GSTT1 gene is possible one of Risk factor of incidence of ovarian cancer,Gene deletion of GSTT1 increase the risk of incidence of ovarian cancer, Increasing the risk of incidence of epithelial ovarian cancer is chief.